Corporate Overview August 2022 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," or other similar terms or expressions that concern X4's expectations, strategy, plans, or intenti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or Washington, D.C. 20549 _____________________________________________________________________________________ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q _____________________________________________________________________________________ (Mark One) (Exact name of re ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Glenn Schulman - Vice President, Investor Relations and Corporate Communications Paula Ragan - President and Chief Executive Officer Adam Mostafa - Chief Financial Officer Diego Cadavid - Chief Medical Officer Arthur Taveras - Chief Scientific Officer Conference Call Participants Marc Frahm - Cowen & Company William Wood - B. Riley Securities Trevor Howard - Oppenheimer Zegbeh Jallah - ROTH ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Glenn Schulman - Vice President, Investor Relations & Corporate Communications Paula Ragan - President & Chief Executive Officer Adam Mostafa - Chief Financial Officer Diego Cadavid - Chief Medical Officer Arthur Taveras - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Marc Frahm - Cowen & Company Mayank Mamtani - B. Riley Securities Arthur He - H.C. Wainwrigh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38295 _________________________________________________________________________________________________________ X4 PHARMACEUTICALS, INC. ...

Investor Presentation March 2022 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," or other similar terms or expressions that concern X4's expectations, strategy, plans, or inten ...

Investor Presentation November 2021 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," or other similar terms or expressions that concern X4's expectations, strategy, plans, or in ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2021 Earnings Conference Call November 4, 2021 9:05 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Art Taveras - Chief Scientific Officer Diego Cadavid - Chief Medical Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Leland Gershell - Oppenheimer Marc Frahm - Cowen & Company Stephen Willey - Stifel Operator Greetings and welcome to X4 Pharmaceuticals Third Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...